Promega, J1631, T Cell Activation Bioassay (NFAT/IL-2)

Measure Stability and Precision of Biologics Designed to Affect T Cell Responses
Prequalified according to ICH guidelines
Amenable to high-throughput formats
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
TCR/CD3 Effector Cells (NFAT) J133A 1 × 0.8ml
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
TCR/CD3 Effector Cells (NFAT) J133A 5 × 0.8ml
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
TCR/CD3 Effector Cells (CPM) (NFAT) J131A 2 × 1ml
TCR/CD3 Effector Cells (IL-2) J129A 1 × 0.8ml
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
TCR/CD3 Effector Cells (IL-2) J129A 5 × 0.8ml
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
TCR/CD3 Effector Cells (CPM) (IL-2) J127A 2 × 1ml
Immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of diseases such as cancer and autoimmunity. T cell activation is initiated by engagement of the TCR/CD3 complex and the co-stimulatory receptor CD28, with TCR/CD3 engagement activating the NFAT pathway and TCR/CD3 + CD28 co-engagement activating NFAT, AP-1 and NF-κB pathways and inducing IL-2 production.
The T Cell Activation Bioassays are bioluminescent cell-based assays that overcome the limitations of existing assays and can be used for the discovery and development of novel biologics such as bispecific antibodies and CAR-T cell therapies.